IGC Pharma, Inc. IGC
0.28
0.00
0.00%
as of 25 Sep
- Market cap
- $29.1M
- P/E
- 0.0×
Follow IGC
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(83.35%) | 0.00% | (112.76%) | (143.46%) | |
| (64.11%) | 0.00% | (78.30%) | (100.44%) | ||
ROIC |
(52.51%) | 0.00% | (79.70%) | (91.53%) | |
Return on Tangible Assets |
(241.91%) | 0.00% | (1,862.07%) | (7,422.03%) | |
Average Days of Receivables |
13.53 | 0.00 | 11.58 | 18.56 | |
Free Cash Flow per Share |
(0.05) | — | (0.04) | (0.06) | |
Free Cash Flow |
(4.83) | — | (4.08) | (5.69) | |
Capital Expenditures |
(0.02) | — | 0.64 | (0.35) | |
Piotroski F-Score |
3.00 | — | 3.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(51.46%) | 0.00% | (64.90%) | (70.56%) | |
Accounts Receivable Turnover |
26.02 | 0.00 | 32.85 | 15.40 | |
Accounts Payable Turnover |
0.85 | 0.00 | 0.66 | 0.58 | |
Inventory Turnover |
0.55 | 0.00 | 0.70 | 0.75 | |
Average Days of Payables |
385.24 | 0.00 | 650.67 | 792.71 | |
Days of Inventory on Hand |
403.65 | 0.00 | 330.78 | 313.56 | |
Tax Rate |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
387.70% | — | 403.77% | 463.31% | |
Selling, General and Administrative Expense of Revenue |
390.42% | — | 379.85% | 481.47% | |
Share Based Compensation of Revenue |
141.32% | — | 187.91% | 225.52% | |
Interest Coverage |
0.00 | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.75 | — | 0.67 | 0.61 | |
Depreciation/Fixed assets |
0.19 | 0.00 | 0.15 | 0.11 | |
Capex/Depreciation |
(0.05) | — | 2.02 | (1.58) | |
Revenue per Share |
0.01 | — | 0.01 | 0.01 | |
Operating CF per Share |
(0.05) | — | (0.05) | (0.05) | |
Capex per Share |
0.00 | — | 0.01 | 0.00 | |
Capex to Sales |
0.02 | — | (0.55) | 0.32 | |
Net Profit Margin |
(582.91%) | — | (602.06%) | (795.46%) |
Columns are period end dates